AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06021938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive virtual reality (IVR) & Music therapy
Description: The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
Study NCT03983473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microbiota Sequencing
Description: virome, bacteriome, fungome NGS sequencing
Study NCT06320236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adjust-Unlikely
Description: Pulmonary embolism will be excluded during emergency department assessment by the combination of:~1. 'Pulmonary embolism is the most likely diagnosis' as per the treating physician AND a D-dimer result \< 500 ug/L fibrinogen equivalent units;~2. 'Pulmonary embolism is not the most likely diagnosis' AND D-dimer \< age-adjusted threshold; or,~3. A negative computed tomography scan, planar ventilation perfusion scan or ventilation perfusion-SPECT.~Emergency departments will use their local laboratory D-dimer assay.
Study NCT04671381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Evaluation
Description: Behavioral thresholds for pure tones will be conducted along with speech perception measures.
Study NCT04671381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hearing Evaluation
Description: Behavioral thresholds for pure tones will be conducted along with speech perception measures.
Study NCT04671381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-Counter Hearing Aid (OTC HA) Fitting and Orientation
Description: Study participants will be fitted with binaural OTC HAs in addition to receiving information on how to use and care for their devices.
Study NCT04671381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Four Weeks of Aural Rehabilitation
Description: Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
Study NCT04671381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Weeks of Aural Rehabilitation
Description: Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
Study NCT04671381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provision of Over-the-Counter Hearing Aids
Description: Study participants will receive binaural OTC HAs. Participants will fit their OTC HAs based on manufacturer guidelines without the help of an audiologist.
Study NCT01048983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
Study NCT06158971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible Bronchoscopic Microwave Ablation
Description: The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
Study NCT04497376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upgraded '2C3L'
Description: Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.
Study NCT04497376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein antral isolation
Description: After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
Study NCT05669508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RISES-T System
Description: Non-invasive closed-loop electrical stimulation of the spinal cord through the skin
Study NCT05669508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational/Physical Therapy
Description: Exercise therapy to improve function of upper and/or lower limbs
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Previous PD-1
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET inhibitor
Description: Previous MET inhibitor
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK inhibitor
Description: Previous ALK inhibitor
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRAF Inhibito
Description: Previous BRAF inhibitor
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR Monoclonal antibody
Description: Previous EGFR Monoclonal antibody
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW or 6mg QD
Study NCT06322095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK Inhibitor
Description: Previous MEK Inhibitor
Study NCT06319768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
Study NCT06319768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
Study NCT06319768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined pentoxifylline and platelet rich plasma
Description: Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
Study NCT06131996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volar supported splint
Description: participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
Study NCT06131996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elastic splint
Description: participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
Study NCT05817435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC as a prefilled syringe presentation
Description: efgartigimod PH20 SC as a prefilled syringe presentation
Study NCT05817435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: efgartigimod PH20 SC as a vial + syringe presentation
Description: efgartigimod PH20 SC as a vial + syringe presentation
Study NCT05730738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release
Description: The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
Study NCT05730738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo similar to Dalfampridine capsule
Study NCT05640726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
Study NCT05640726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: Radiotherapy dose: 5×5 Gy
Study NCT05640726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
Study NCT05640726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive Oxaliplatin，85mg/m2，day1
Study NCT05640726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Participants will receive calcium folinate ，400mg/m2，day1
Study NCT05640726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Participants will receive 5-fluorouracil ，400mg/m2，day1
Study NCT06437821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Petrissage
Description: The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
Study NCT06437821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston Technique
Description: The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
Study NCT05197647 — intervention group
Intervention type: OTHER
Intervention: Patients with symptomatic COVID-19 disease not requiring hospitalization.
Description: Patients with symptomatic COVID-19 disease not requiring hospitalization.
Study NCT05266105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palazestrant
Description: Complete Estrogen Receptor Antagonist
Study NCT05266105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an approved CDK 4/6 Inhibitor drug
Study NCT05538182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
Study NCT05082142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
Study NCT04717973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory testing of CBC, serum ferritin, and vitamin B 12
Description: laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass.
Study NCT06019013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF3108
Description: QLF3108 will be administered independent of body weight.
Study NCT05885035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxyapatite
Description: Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
Study NCT06320015 — intervention group
Intervention type: BEHAVIORAL
Intervention: Substance Misuse Assistance Response Team (SMART)
Description: The study intervention is engagement with a Substance Misuse Assistance Response Team (SMART) community health worker-peer recovery specialist (PCHW). SMART PCHWs engage ED patients with substance use disorders and facilitates ED services provision and linkages to outpatient care. Services provided include supporting ED initiation of buprenorphine, harm reduction services, social services (transportation, housing assistance, etc.), and engagement in peer recovery, behavioral health services, and addiction treatment services. Services are provided at the time of the ED visit. A subgroup of patients is provided short term case management and outpatient services navigation depending on PCHW caseload availability and individual needs.
Study NCT06320015 — intervention group
Intervention type: OTHER
Intervention: Usual Care Group
Description: Patient not seen by a SMART community health worker in the emergency department. Care and treatment referral at discretion of emergency department treating team.
Study NCT06419543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Observe the incidence of paradoxical reactions after the first induction.
Study NCT05814016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton IV infusion.
Study NCT05814016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching danavorexton IV infusion.
Study NCT05897086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
Study NCT05537441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text messaging
Description: Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
Study NCT05537441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
Study NCT05440435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: digital radiography (DR)
Description: Patients with bone injury received routine and mobile DR sequential examination.
Study NCT04688528 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose de-escalation and / or Volume de-escalation
Description: The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
Study NCT04639778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Clinical visits conducted by a multidisciplinary team every year
Study NCT04639778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Clinical visits are triggered by weight evolution measured by connected balance
Study NCT05193617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+Penpulimab+Anlotinib
Description: GP combine with penpulimab and anlotinib neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
Study NCT05193617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP+Penpulimab
Description: GP combine with penpulimab neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
Study NCT04894149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
Study NCT06489327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin (Circadin ®) 0.2 mg/kg
Description: Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study NCT06489327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin (Circadin ®) 0.4 mg/kg
Description: Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study NCT06489327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study NCT06062602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-676
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-676 + Carboplatin
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin + Paclitaxel
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin + 5-FU
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-676 + Carboplatin + 5-FU
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06062602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-676 + Carboplatin + Paclitaxel
Description: Intratumoral microdose injection by the CIVO device.
Study NCT05417334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Capicitive Monopolar Radiofrequency
Description: 5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
Study NCT05417334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Resistive Capicitive Monopolar Radiofrequency
Description: 5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
Study NCT04906109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy Tab
Description: 1T
Study NCT04906109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803 Tab
Description: 1T
Study NCT05534880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Binaural beats
Description: Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
Study NCT05534880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural beats
Description: Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
Study NCT04861285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RACESTYPTINE Solution with cord
Description: The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
Study NCT04861285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RACEGEL with cord
Description: The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.